The preliminary study of Ganoderma lucidum broken spores on immunoglobulin levels and its safety in cancer patients after completion of chemotherapy


  • Philailak Tangkhaphiphat Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences and Bioactive Resources for Innovative Clinical Applications Research Unit, Chulalongkorn University
  • Tippawan Siritientong ภาควิชาอาหารและเคมี คณะเภสัชศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย
  • Sureerat Jaruhathai กลุ่มงานอายุรกรรม โรงพยาบาลตำรวจ
  • Natta Pipopchaiyasit กลุ่มงานเคมีบำบัด สถาบันมะเร็งแห่งชาติ
  • Tanchanok Ratanajarusiri กลุ่มงานเคมีบำบัด สถาบันมะเร็งแห่งชาติ
  • Pornanong Aramwit ภาคเภสัชกรรมปฏิบัติ คณะเภสัชศาสตร์ และ หน่วยปฏิบัติการวิจัยสารทรงฤทธิ์ชีวภาพเพื่อนวัตกรรมทางคลินิก จุฬาลงกรณ์มหาวิทยาลัย
Keywords: Ganoderma lucidum, Immunoglobulin, Chemotherapy, Safety, Cancer


Ganoderma lucidum (GL), known as ‘Lingzhi’ has immunomodulatory effect to stimulate immune cells, such as B cell, immunoglobulin (Ig). The duration of those cells’ recovery after chemotherapy completion was longer than 9 months. The objectives of our preliminary study were to evaluate the effect of GL broken spores (GLBS) on immunoglobulin levels and its safety in patients after chemotherapy completion. Fifteen cancer patients after completion of chemotherapy were informed to take 750 mg of GLBS per day divided into three doses before meals for 8 weeks. The results showed IgG, IgM, IgA and IgE levels were not significantly difference compared before and after this study (p-value: 0.34, 0.53 and 0.95, respectively). Mild adverse events such as dry mouth, headache, pain, oral wound, and constipation were found. No significant changes of renal and liver functions were observed. The results suggested that consuming GLBS at 750 mg per day might not be effective for increasing immunoglobulin levels after completion of chemotherapy.